ClinConnect ClinConnect Logo
Search / Trial NCT02589405

Benzac 5% Gel in Combination With Cosmetic Products in Acne Vulgaris

Launched by GALDERMA R&D · Oct 27, 2015

Trial Information

Current as of April 25, 2025

Completed

Keywords

ClinConnect Summary

The main objective of this study is to evaluate subject satisfaction with the treatment regimen comprising Benzaknen® 5% Gel in association with 2 cosmetic products including a foam soap, Dermotivin® Soft Liquid soap, and a non comedogenic moisturizer, Cetaphil® Dermacontrol Moisturizer SPF30, in patients with mild to moderate acne, after 12 weeks of treatment.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Male or female subject of any ethnic background of 12 years or older.
  • Subject with mild or moderate facial acne vulgaris defined as an Investigator Global Assessment (IGA) score at 2 or 3 on a 0-4 scale.
  • Subject with any skin phototype according to T.B. Fitzpatrick skin phototype definitions.
  • Exclusion Criteria:
  • Subject with severe acne (IGA\>3) with nodules, cysts, scars or extra-facial lesions,
  • Female subject who is pregnant, lactating or planning a pregnancy during the study,
  • Subject susceptible to take a corticosteroid treatment during the study except inhaled or topic when needed to treat a condition outside the face,

Trial Officials

Mi-Ran EGBERT, MD

Principal Investigator

Proinnovera GmbH

About Galderma R&D

Galderma R&D is a global leader in dermatological innovation, dedicated to advancing skin health through rigorous research and development. With a strong commitment to scientific excellence, Galderma focuses on creating effective and safe treatments for a variety of skin conditions, including acne, rosacea, and psoriasis. The organization collaborates with healthcare professionals and researchers worldwide to bring cutting-edge solutions to market, ensuring that patients receive the highest quality care. Through its extensive clinical trials and commitment to regulatory compliance, Galderma R&D strives to enhance the understanding of dermatological diseases and improve patient outcomes.

Locations

Münster, , Germany

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials